MedPath

Zinc Supplementation in Cirrhotic Patients

Not Applicable
Conditions
Dysgeusia
Liver Cirrhosis
Registration Number
NCT02475928
Lead Sponsor
Fundación Clínica Médica Sur
Brief Summary

The purpose of this study is to evaluate the effect of zinc supplementation in the treatment for dysgeusia, progression disease and quality of life in patients with liver cirrhosis.

Detailed Description

Taste disorders are symptomatologies in patients with cirrhosis, these have a direct effect in modification of food consumption, increasing weight loss, anorexia and malnutrition, which impacts in decompensation rates and mortality.

It has been proposed that zinc deficiency is one of the causes for development of taste disorders. The aim of this study is to describe the presence of taste disorders in patients with cirrhosis and evaluate the effect of zinc supplementation in treatment of taste disorders, and in progression of chronic liver disease.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Cirrhotic patients by any etiology, with any dysgeusia
Exclusion Criteria
  • Patients with hepatic encephalopathy at the time of dysgeusia evaluation
  • Patients with any neurological disease
  • Patients with respiratory diseases ath the time of dysgeusia evaluation
  • Patients with active alcohol consumption

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
DysgeusiaPresence of any taste disorder at 6 months

Evaluation of presence of any taste disorder, according to questionnaires and evaluation of perception and recognition thresholds with ascending molar concentrations of basic tastes.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medica Sur Clinic & Foundation

🇲🇽

Mexico City, Mexico

Medica Sur Clinic & Foundation
🇲🇽Mexico City, Mexico
Varenka J Barbero-Becerra, PhD
Contact
54247200
vbarberob@medicasur.org.mx

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.